Similar articles

• Chemotherapy in epithelial ovarian cancer.

  Wang J, Li AJ, Karlan BY. Wang J, et al. Curr Womens Health Rep. 2002 Feb;2(1):20-6. Curr Womens Health Rep. 2002. PMID: 12112979 Review.
• Critical evaluation of secondary cytoreduction in recurrent ovarian cancer.

  Munkarah AR, Coleman RL. Munkarah AR, et al. Gynecol Oncol. 2004 Nov;95(2):273-80. doi: 10.1016/j.ygyno.2004.09.018. Gynecol Oncol. 2004. PMID: 15491746 Review.
• [Secondary debulking operation in ovarian cancer].

  Jänicke F, Schattenmann G, Kuhn W, Graeff H, Siewert JR. Jänicke F, et al. Chirurg. 1994 Jan;65(1):10-7. Chirurg. 1994. PMID: 8149793 Review. German. No abstract available.
• Second-line treatment of first relapse recurrent ovarian cancer.

  Chua TC, Liauw W, Robertson G, Morris DL. Chua TC, et al. Aust N Z J Obstet Gynaecol. 2010 Oct;50(5):465-71. doi: 10.1111/j.1479-828X.2010.01209.x. Aust N Z J Obstet Gynaecol. 2010. PMID: 21039382 Review.
• [Standard of chemotherapy in ovarian cancer].

  Pfleiderer A, Meerpohl HG. Pfleiderer A, et al. Chirurg. 1994 Jan;65(1):18-22. Chirurg. 1994. PMID: 8149794 Review. German. No abstract available.